Intro offer
100 days of Premium for just $10.
Try all Premium features for over 3 months and analyze stocks without limits.
Try 100 days for $10

$5.50
0.00%
Nasdaq, Tue, Sep 15 2026.
ISIN
US14888D2080
Symbol
CSCI

Catalyst Biosciences, Inc. Stock price

$5.50
-0.14 2.55% 1M
+1.33 31.80% 6M
-0.68 11.07% YTD
-2.42 30.61% 1Y
-26.30 82.72% 3Y
-180.14 97.04% 5Y
-1,008.50 99.46% 10Y
-1,158,853.76 100.00% 20Y
Nasdaq, Closing price Tue, Sep 15 2026
+0.00 0.00%
ISIN
US14888D2080
Symbol
CSCI
Industry

Is Catalyst Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,143 stocks worldwide.

Key metrics

Basic
Market capitalization
$5.4m
Enterprise Value
$2.1m
Net debt
positive
Cash
$5.3m
Shares outstanding
1.1m
Valuation (TTM | estimate)
P/E
0.9
P/S
0.7 | -
EV/Sales
0.3 | -
EV/FCF
negative
P/B
0.4
Financial Health
Equity Ratio
17.9%
Return on Equity
-269.6%
ROCE
-30.2%
ROIC
-42.7%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$8.3m | -
EBITDA
$-3.8m
EBIT
$-5.0m
Net Income
$6.6m
Free Cash Flow
$-3.8m
Growth (TTM | estimate)
Revenue
-12.3% | -
EBITDA
78.1%
EBIT
73.1%
Net Income
134.8%
Free Cash Flow
79.2%
Margin
Gross
45.4%
EBITDA
-45.5%
EBIT
-60.6%
Net
79.1%
Free Cash Flow
-45.6%
More
EPS
$6.3
FCF per Share
$-3.6
Short interest
0.3%
Employees
28
Rev per Employee
$270.0k

Catalyst Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Catalyst Biosciences, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Catalyst Biosciences, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Catalyst Biosciences, Inc.

Jun '26
+/-
%
8.28 8.28
12% 12%
100%
- Direct Costs 4.52 4.52
10% 10%
55%
3.76 3.76
15% 15%
45%
- Selling and Administrative Expenses 7.03 7.03
37% 37%
85%
- Research and Development Expense 1.43 1.43
81% 81%
17%
-3.77 -3.77
78% 78%
-46%
- Depreciation and Amortization 1.25 1.25
16% 16%
15%
EBIT (Operating Income) EBIT -5.02 -5.02
73% 73%
-61%
Net Profit 6.55 6.55
135% 135%
79%

In millions USD.

Don't miss a Thing! We will send you all news about Catalyst Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Catalyst Biosciences, Inc. Stock News

Neutral
GlobeNewsWire
7 days ago
WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 58,650 shares...
Neutral
Business Wire
13 days ago
BOYNTON BEACH, Fla.--(BUSINESS WIRE)-- #CSCI--CSCI secures 12 new residential projects totaling 2,926 units across Florida as the structural shell contractor continues to gain market share.
Neutral
GlobeNewsWire
about one month ago
WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 19,425 shares ...
More Catalyst Biosciences, Inc. News

Company Profile

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on August 20, 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Mr. Puccetti
Employees 28
Founded 1997
Website www.cosciensbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today